Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you so much. Good morning and good afternoon, everyone, and welcome to XVIVO's earnings call for the first quarter of 2026. We can go to slide number two. And today's presenter is myself, Christoffer Rosenblad, calling in from the ISHLT 2026 Conference in Toronto, Canada. And Christoffer Nordström, CFO, calling in from Philadelphia in the United States. And with that, we can go to slide number three. Financial at a glance. So, the first quarter of this year showed a 23% organic top-line growth. This is equivalent to an 18% organic top line growth if we adjust for the US CAP trial revenue compared to the same quarter last year. EBITDA remained at a healthy level, resulting in a positive cash flow for the second consecutive quarter. The CFO, Christopher Nordstrom, will be getting more into the details on sales, gross margin, and EBITDA later in this presentation. Briefly on the segments. Both the thoracic and abdominal segments are growing rapidly in both regions, North America and Europe. The lung market trend we saw in Q4 last year continued into Q1 2026, showing good underlying growth. And we see that a larger sales footprint supporting more customers is paying off. Also very pleased with the strong kidney sales in the quarter, partly fueled by the Canadian launch and a growing interest in the United States. We will come back later in this presentation on the progress for the service segment. The actions we have taken and how we will execute to become the preferred partner to all the transplant teams, and with that, we can go over to the Highlights of the quarter. And we can actually jump straight to slide number five, which highlights a very busy quarter. We took many important steps last year and this quarter, and we have passed many important milestones that led to another record quarter, marking our first highlight. Secondly, the very important OPO EVLP hub pilot has been very successful and is now up and running. And this partly explains the increased lung sales we are seeing this quarter. So far, the progress is ahead of our internal plan, and we have identified 4 to 5 more hubs in the rollout pipeline plan, whereof the second OPO in that plan will be onboarded already now in Q2. In parallel, we are continuously investing in more feet on the ground in the United States. To enable closer customer relationships with the growing number of EVLP partners we see, and we can also report that the 60-patient CAP trial enrollment is now complete during the quarter. We had an extremely high interest from trial centers to use the technology, and to satisfy their needs. We have had to use Heart Assist. We have asked the FDA for an extension of the CAP so they can use it again under the IDE we have. And if we look at number five, it's a testament to how well the XVIVO Heart Assist performs. And it's best shown with the real-life experience in Australia. So, during Q1, the penetration increased to 52% for DBD heart. And we're happy to announce that we did our first DCD heart in Australia now as well. It's a very important milestone and makes us convinced that we should aim to become the global gold standard for preservation of all hearts. And while we're waiting for the last part of the CE-mark for heart, we should mention that both the machine and disposable are already CE-marked. More and more European agencies are approving the Heart Assist device for compassionate use. And we actually saw sales in Europe picking up already now in Q1. This is again an indication that the European transplant teams can't wait for the device that optimizes heart preservation and enables more hearts to be used for patients waiting for new hearts. In our service business, we saw good progress in the Flowhawk part of it, with high growth and new customers opting to use the communication software; already, six out of ten of the largest transplant programs in the US opted to use Flowhawk, since it simplifies the transplant process and reduces overall costs in the process. Then we're going. Recovery business is now ready for growth, and we have a positive outlook for the rest of the year. We offer NRP if needed, as there is increased interest to use the XVIVO organ recovery service. I had many, many good conversations during this ISHLT, for example. And with all those highlights, we can go to the deep dive into the highlights on slide number six. So as I said earlier, I'm right now in the middle of the ISHLT conference, which is the biggest lung and heart transplant Congress in the world. And after spending time here, it is clear that XVIVO was by far the innovation leader in the field of both lung and transplantation. For example, the heart device was featured in two late-breaking news sessions that were very well attended and increased interest from clinics. I won't elaborate on the Heart Assist Transport now, nor will I delve into those sessions. We have some press releases regarding those, but we will go into those later on the next slide. I also want to highlight that very soon after this meeting, we will have our heart symposium, which will be really, really interesting to see. But already this Wednesday we had the lung symposium. So it was an industry-sponsored Lung Symposium, which was a great success. It really had extremely high attendance, created a lot of interest from future customers to start up EVLP program. And it was also very clear that with new innovative technology on the market, the field of lung transplant has improved significantly over the last decade. For example, over the last five years, the number of DCD lung transplantations has more than tripled. More importantly, patient outcomes also improved, and over the last ten years, the one-year survival for extended-criteria and DCD lungs has gone from 85% to above 90%. And it's now on par with what we call normal lungs. And there we see that the adoption of EVLP has been key to enable safe use of those extended criteria organs. But let's jump into the two highlights in the late-breaking news session from XVIVO. So we go to the next slide, which is number seven. And it was the US PRESERVE trial that was presented. Again, the clinical results from investigational use are positively surprising us on the heart side. The trial was performed at 14 clinics in the US, and they enrolled a total of 141 patients. The US study aimed to prove that extended criteria could be utilized. Hearts, as described on the slide here, could safely be transplanted using the XVIVO system. I'm happy to announce that the study met its predefined efficacy and safety endpoints. The sub-analysis of the secondary endpoint also showed that severe PGD was only 7.9%. Severe PGD is the leading cause for early and late mortality in heart transplantation. I will come back later here on the importance of it when we look over the European data. And the next step is that we will now finalize the file for submission to the FDA for their review. And then we can turn to slide number eight, which is the other late breaking news, which was a very well received presentation. From the European DCD direct procurement experience with DCD hearts. The trial was a single-arm proof-of-concept trial. A total of 40 adult heart transplant recipients across four European transplant centers in Belgium and the Netherlands were enrolled. And the primary endpoint for patient survival at 30 days was 98%, which is very high. And the secondary endpoint of severe PGD was only 5%. Again, showing that the effective preservation of the heart reduces complications after heart transplantation. I also want to mention looking forward that if the method of direct procurement is widely accepted by the heart transplant community, it would significantly reduce cost in the transplant process and simplify for the transplant teams around the world. And with that, we can go into the EU trial, which is now in publication during Q1 this year. I again want to mention this is the first randomized control trial with a primary endpoint that was ever performed in the field of heart transplantation. So no one dared to try this before, but we did. It is also the first clinical trial to establish a link between preservation method, severe PGD reduction, and reduced one-year mortality. And you can see this in the data. If you look at the little box of data, both mortality and severe PGD have a clear link. And I will explain that link. So, in the analysis of the trial data, it was noted that the XVIVO group had a reduction of severe PGD by 76%, with the incidence being 20% in the control group and only 5% in the XVIVO group. It was further noted that the mortality after severe PGD was approximately 40% in both groups, leading to an increased survival of 6% in the group versus the control group. We can also note here that the primary endpoint showed statistical significance at day 365, which is good. With the experience we have seen in Australia with more than 50% of all DBD hearts now being preserved on the XVIVO system, and those three trials that we have recently presented, the body of evidence in favour of XVIVO is increasing significantly, which is great news. And with that, I will go over to the regulatory update on slide ten, and we can actually go straight to slide 11, which is the usual overview of our regulatory processes. So the US PRESERVE trial was fully included in record time, and we now have passed the 12-month patient follow-up. And you saw the result of that during the late breaking news session of ISHLT and the press release we sent. We are now preparing the regulatory file. And when ready, we will submit the file to the FDA for their review. The CE marking process in Europe is ongoing, and we are awaiting feedback from one competent authority. But again, as stated earlier, the Heart Assist Transport system and its disposable products are already CE marked. And we have passed the EMA consultation, and we are now awaiting that last consultation. Again, I also want to confirm that we are ready to launch when the product is fully approved. So we have a launch plan ready, we have staff recruited. And the interest from clinics in Europe is very high. And as I stated earlier, we actually saw some sales already from compassionate use this quarter. But unfortunately, the European clinics are suffering badly from the lack of alternatives to the water system. So we are working really hard with our notified body to get the final CE mark. But we are happy to see and hear all the engagement from our heart transplant clinics in Europe. Who just want to get it up and running. Also, we mentioned previously that Australian and possible Canadian approval will follow on the CE-mark. So we will use that as a base. We will come back to the US liver update on the next slide, actually, so we can go straight to that slide. And slide number 12. The liver regulatory status. So we have previously reported that Liver Assist has been granted Breakthrough Device Designation by the FDA. We have an approved IDE and CMS funding approved. We could have started a trial last year. We did decide to temporarily pause activities for the liver PMA process to investigate an alternative regulatory route. And we are currently preparing for an FDA submission where the possible regulatory pathways will be further outlined. And the company and I will come back and inform all investors of the next step in the US liver regulatory investigation later. So of course, when we report the Q2 report in July, I will give an update. And with that, I hand over to our CFO for going into the financial performance of XVIVO. Thank you.
Thank you. And happy to do so, Christoffer. So the financials for the first quarter, this was a record sales quarter with clear signs of growing momentum. As Christoffer mentioned, especially in our core business and across all main markets for the first quarter. For the second quarter in a row, the strong sales momentum translated into a positive net cash flow despite continued investments into our clinical and regulatory processes. So we're very happy about that. Net sales in Q1 were 241 million. Second, organic growth was 23%, and 18% excluding revenue from the CAP trial. Gross margins were 71%, while Thoracic margins remained strong. The gross margins in abdominal and services were softer, which will be explained when I go through each business area here. In a little while, our continued focus on cost consciousness continues to translate into healthy EBITDA levels. EBIT was 13% and EBITDA 21%. The quarter was impacted by 7 million. HeartAssist. Go-to-market preparations. Non-recurring items, which explain the increase in administration costs. Setting this initiative aside, the underlying EBITDA in Q1 was 24% and more in line with what we saw in Q4 last year. Moving over to thoracic. The thoracic business area accelerated in Q1 and delivered record sales of 160 million. Organic growth was 27%. And excluding CAP trial revenue, 19%. In regard to lung. The momentum for LP continues to evolve positively. LP Disposables grew 56% in Q1, and the main customer segments, the centralized perfusion hubs and larger key accounts grew double digit. And we're very satisfied with the early phase of the perfusion partnership that we launched in Q4 with OPO, as we now have proof of concept from the first OPO LP hub. Ten EVLPs have been performed since the introduction of this program, with good learnings and great collaboration. We also have a second OPO that was onboarded in early April, and we are hopeful that this partnership will be equally successful, of course. So this is a very exciting initiative that can have a significant impact for lung transplant patients on the waiting list in the US and can have a strong impact on the EVLP adoption over time. In regard to heart. Q1 was a very good quarter. The CAP trial, as Kristoffer mentioned, included its last patient in the US and Australia. New Zealand continues with extraordinary market penetration under compassionate use. And finally, what is very encouraging is that we now have a handful of countries in Europe as well, where hospitals have worked hard to get the temporary special permits in place to be able to use the technology. And all this in wait for the CMS approval, of course. Gross margin 83% in line with last year. And this means that we have successfully increased prices to offset impacts from tariffs and also from a weakened US dollar. So overall, Thoracic is experiencing good momentum, moving over to Abdominal. Abdominal continues to deliver good quarters. Net sales were 66 million SEK and equaled an organic growth of 24%. Liver sales grew 12% in local currencies to 45 million SEK. Kidney was the shining star of the quarter in Abdominal. Sales grew 63% in local currencies. We see a growing interest for kidney transport in North America, both in the US and Canada, and Q1 brought new accounts both for clinical and research use. With a few important congresses coming up here in Q2, we are optimistic that the good traction for Abdominal will continue as the year progresses. When it comes to gross margin in Q1, the gross margin was 54% versus 63% last year. The decrease was mainly a result of a larger portion of kidney sales versus liver, but also a larger portion this quarter of sales to lower-price markets such as Asia, South America, and Eastern Europe. But once again, a solid quarter for abdominal as we continue to build a market for liver and continue to take market share in kidney. Moving over to Services, our last business area, net sales were 60 million SEK, representing a -10% organic growth. The two areas, Flowhawk and Organ Recovery Services, showed mixed results. Flowhawk showed an impressive growth of 62% as a result of both new customer acquisitions and upgrades and renewals in Q1. The largest transplant program in the United States decided to implement Flowhawk. That's a true feather in the cap for the Flowhawk team, which means the software is now embedded into the day-to-day practice at six out of the ten largest transplant programs in the country. And we'll continue the investments into Flowhawk. We believe it truly has the potential to become the future golden standard of transplant workflows and secure communication in the field. Organ recoveries showed yet another quarter with negative growth -10%. As I stated during the Q4 earnings call, we last year put a surgical organization in place that will enable us to return to growth in 2026 and beyond. Today, we have surgical capacities to significantly increase the case volume. And with this month as a starting point, our focus from now on will lie heavily on marketing and sales execution. Gross margin decreased to 18%, and this was purely due to the lower case volumes for organ recovery. At the same time, we incur fixed operational costs, keeping our surgical teams on call 24/7. But with an increase in cases, our gross margins will improve to more sustainable levels. EBITDA, or profitability, was strong for the second consecutive quarter, at 21%, and excluding non-recurring costs, it was 24%. So rolling 12, we're at 20%. And we are on a positive trajectory on the rolling 12 KPI. In the following quarters, we will continue to manage our operating expenses with discipline and ensure resources are directed toward initiatives with clear commercial returns. Investments will mainly be directed to sales and clinical field force to capture the significant market opportunity that lies ahead of us. Being an all organ company. And my final slide for the day here. Cash flow. And we're ending with some positive news here. So for the second consecutive quarter, we ended up with a total positive cash flow. Operating cash flow was 65 million SEK, mainly driven by good sales momentum, of course. And the cash flow from investments was 55 million SEK. But all in all, we ended up for the second quarter in a row with a positive total cash flow, and we have 308 million SEK at hand when we close the quarter. And with those final remarks, Christoffer, I will give the word over to you again. Good luck with the end of the conference here.
Thank you. And with that, we're going to go into the outlook and look a bit into the future of what will happen this year and also what will happen in the long term. And we can go to slide number 21, really focusing on this year and the activities we have for this year. And again, we are going to continue to build our sales force and new partnerships, especially in the US, to enable OPOs and clinics to recover more lungs by EVLP adoption through a combination of a service model and staying very, very close to customers. In parallel, we just heard from our CFO that we will increase our service offering and better tailor customer needs. Now we are offering NRP procurement from an increased footprint of surgical teams that can stay close to customers and recover organs with high quality. We will continue to work closely with competent authorities in Europe to be able to use the Heart Assist Transport as much as possible already now. And we are aiming to obtain a CE-mark as soon as possible and waiting for the last part there. Another key milestone. Now, with the data from the US PRESERVE trial, presented at ISHLT, we will now submit the regulatory file to the FDA for their review during the summer. And we also talked about Liver Assist. We will come back with more information on the regulatory route. But we know that Liver Assist is soon becoming the gold standard in Europe. And we save hundreds of lives every quarter using Liver Assist. And now we want to continue to support clinics in Europe and also give US clinicians the ability to actually use the Liver Assist system and have the same success we have seen in Europe. We go to the next slide 22 and a little bit longer-term outlook. And I want to state this on every call, for this is the reason we are here. We know that a lot of patients with end-stage organ failure are dying every day. Some of them are on the waitlist. But the majority never even make the waitlist. So the demand for transplantation is, according to our analysis, approximately one hundred times today's supply. We also see that the sales value of machine perfusion that improves patient outcomes and safely increases the usage of donated organs, versus cold storage, is also approximately ten times in terms of value. So we see a market opportunity which is almost 100 times what we see today. And we know that the machine perfusion and the service model have a proven track record. And that's really been clear here, as we have effectively increased the number of organs used for transplantation and safely increased them, with an improving survival rate as well. And we also know that we see a growing DCD organ pool; in many countries, it's about 50%, and in the US, it is now hitting the 50% mark. And we have clear evidence that machine perfusion is needed to safely address the DCD organs. So at XVIVO, we want to change the paradigm of transplantation through innovation. And we want to be very clear that we believe that innovative products and innovative perfusion and preservation solutions are the key for the future. And we do have a unique, very innovative, and world-leading product in the market or under IDE trials. Uh, so we believe in the longer term that we will lead this market due to innovation over time, enable lower cost and transplant process. And we think that will be very important going forward. And with that, we turn to slide 23 and open up for questions.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Simon Larson from Danske Bank. Please go ahead.
Yes. Good afternoon everyone. Firstly, maybe on the US heart theme, I noted in the press release from Wednesday that you are planning to hand in the file to the FDA later this year, but could you give us any more details on when that might be, which would be helpful?
Thank you. Good question. We are sitting with the file right now. I don't have an exact timeline, but it will be somewhere during the summer. So I will come back when I have a better timeline during the summer. So it's not the end of the year. It's earlier than that.
Understood. And maybe it's a bit speculative at this point, but. But would you expect the FDA to summon an advisory committee ahead of a potential approval or. What's your thinking around that dynamic?
I can't speculate on what the FDA wants. We have to hand in the file and see what the feedback is and follow their process. It will be more or less impossible to speculate on what will happen or not. But I know last time we had an expert panel meeting, we fared very well with a vote of 10 to 0. So we know how to do this, and we are confident that we can answer any question the FDA might pose to us.
No, sir. Sir, I know you said in the beginning of the presentation, Christopher, that you aim to make the heart box a standard of care for all hearts. But if you could help us understand the scope of the hearts that you will address in the US, maybe to begin with, we'll be focusing on the sort of marginalized extended criteria donor (ECD) or DCD hearts, or those from older donors. Any help slicing the market opportunity and what you will target first? Would be also interesting to hear.
That's a great question. We can only market what we get on the label. And the label will be pending the FDA review process. So, it's hard to say exactly. But if we look at the US PRESERVE trial and the inclusion exclusion criteria there, it is exactly those hearts we're talking about. It's DCD heart, extended criteria. Heart. So that's either due to more than two hours of preservation and a couple of factors. A couple of risk factors. All hearts with more than four hours of preservation. So we will definitely target those hearts. We also see an increasing interest here from clinicians. So, we will have a quite broad target when we launch the product to make sure that we can reach all clinics as soon as possible after day one of the launch.
Makes sense. Maybe then the final one from my end, turning a bit to the lung part of the business. Obviously, the EVLP part is doing very well here. Could you say anything about the pipeline, how it looks for new accounts, both in terms of new centers and OPOs, of course. And honestly, if you're happy with the revenue generation from the new accounts that you signed last year, and also your visibility for the lungs in the coming couple of quarters as well.
What we hear from ISHLT is that there is a growing interest for an EVLP program. And we do see great progress now both in underlying market growth, where we see that more and more data is getting published, showing that using EVLP for extended grafts or DCD grafts has a really positive impact on the overall survival and that we use more organs. So, in general, there is a good underlying trend for the lung market. The other thing which we are working with is to put that technology into more hands, so to say. So we can do it. And especially the hub model that one OPO over one center pumps lungs for a larger area, which we have seen has been very successful before. So we have a positive outlook. But again, looking into the future, it's impossible. But what we can see so far, it looks very good. And especially I'm really encouraged after all the meetings we had here in both the lung symposium and all the customer interactions from the ISHLT. We see positive outlook.
Gotcha. Great. Thanks so much.
Thank you.
The next question comes from Ulrich Ratner from DNB Markets. Please go ahead.
Thank you very much. And I have a few questions on my end, and I'll start with the abdominal gross margins. And Christoffer, you touched upon this, but I also note that the gross margin was kind of equally low in Q4. So, are there aspects related to this since you moved your manufacturing to Sweden from the Netherlands, or is it just market product mix that we should expect to revert here in the short term?
I can start a little bit high level and then Kristoffer Nordström, if you want to pitch in on this one. But at a high level, there are today, at least in the abdominal segment, slightly lower gross margins. Gross margins in Europe versus the US. So it's partly a regional mix that we hope over time we will grow out of. Also, we are moving production right now and have not reached their full scale in production that we want. So it's not, let's say, a quick fix, but we diligently work to improve the gross margin for our abdominal portfolio in the next quarters and years to come. So we see a gradual improvement, is my belief.
I agree, I can just add as well, Christopher, that we do expect to see growing gross margins for abdominal. What will impact that is, of course, when we start to see a stronger ramp up in the United States. It was a good quarter. In North America, Abdominal sales this quarter. But it was partly research sales. That over time, of course, will translate into more clinical sales, so to say. But it's still very much about our European business, with some regions with lower pricing.
Okay, great. And on to prospects going ahead and the Q-sub meeting that you have scheduled. So what is your ambition going into this Q-sub meeting? You can obviously go down a few routes here, but are you aiming to use the European data in order to get approval as it did for kidney? 510(k)? What is the most feasible and reasonable pathway forward here?
It's a great question. Of course, we are aiming that, but we will have a dialogue with FDA. We had a very positive meeting earlier this year. And we will continue in a more official meeting with them to get a firm route forward. We, of course, aim to leverage as much of the European data as possible, but we would also be in listening mode and see what the requirements from the FDA are. So there will be a good dialogue that we have started that is very good and positive, but we also have to be humble that the FDA is deciding in this case. So we will argue our case and see what comes out of it.
And just correct me if I'm wrong. But wouldn't it be beneficial in your end to actually generate some U.S. data prior to launching it? In hindsight, what we have seen with the kidney launch is that US data is of high importance in order to reach higher volume. So potentially a 510 K would be the preferred route in your end.
The good news with the 510 K route is that the burden of proof is less, and it's more towards safety than efficacy. But you're right in any way. Whatever the FDA says, we need to do a trial, whether before or after. So we will do a clinical trial in the U.S. to make sure that American users can replicate the European data. That is extremely good for it to be believable. And you're right, with the kidney experience, we learned that very fast that launching product without US data will not make it fly. So we have to do something either way. But we're still aiming to leverage as much as possible of the very positive European data. It is by far the largest body of clinical data we have for short and long-term results, which are all very positive. So that is, of course, our aim.
Okay, great. And the question on the CAP trial is, if you went from four patients in Q3 2022. And now 36 here in Q1. And I would assume that the interest has not gone down post ISHLT, I hope so. How quickly can you get a pre-approval or expansion of your CAP program in the US?
We're aiming as soon as possible. It is under review from the FDA, and they will come back to us soon, according to what they said. But again, it's hard to speculate on the FDA timeline and the work burden they have. But what we can say is that the interest is extremely high from US clinicians before the ISHLT and before those two presentations. And it has increased significantly after. So that is very clear.
And can you give some type of indication on just the penetration per active site in the program. Are they using it on all of their hearts that are being transplanted, or is it just a portion of them? Or can you give us any more sort of insight? That would be very interesting.
That's a good question. We should remember right now that this is a scarce resource for them. There is a limited number of patients, so they only use it on the worst grafts and the sickest patients where they see no other use right now. So we should remember that, but we can see in some CAP centers there is quite high penetration. And the testimonial I get when I'm here from the users is that this is so easy to use. It's really plug and play and the hearts are in an excellent condition after being in a state of heart disease. Some have quite high penetration. But we should remember that it would be higher if we had an approval or, let's say, an unlimited use, because now it's capped to a number of patients. And I think it's more interesting to look to the Australian situation, where there are uncapped continuous access protocols or similar, and there we see that it's 50% for DBDs. And now we're starting with DCD.
Regarding the data you have generated recently, including the positive outcomes in the US and for additional patients in Europe from the HOPE trial, are you submitting this to the European regulatory agencies, and has this in any way increased your confidence in obtaining approval for the heart box in 2026?
The straight answer is yes. The feedback we get from those compassionate uses is that we don't see any alternative on the market for any grafts, pediatric, adult, DCD, or DBD. So it's really encouraging to see regulatory agencies in Europe looking into the file. They clearly state there is no alternative. We need compassionate use for this product, and so, yes, the straight answer is yes. We get more confident the more we talk to medical agencies, the more we talk to clinicians, about how important this is. But again, the regulatory process is a regulatory process, and it's hard to speculate. But definitely we are. Due to this, we are more confident. Yes.
Great. And last question on my end. Did you mention that you had found 45 OPO targets to be integrated into an EVLP program? I just wanted to confirm if I heard that correctly.
45 are identified in the pipeline right now. To clarify that, we have done our first installment very successfully ahead of plan. We are doing our second one, I believe, as we speak, or it will be very soon. And then there is a rollout plan, which to some extent will be resource-limited, but we have a clear plan and we're going to make sure that we are successful in every installation. So we're going to make sure that we are done. And we are also increasing our internal resources to be able to handle that and increased growth and increased interest from OPOs. In all honesty, the XPS and the service solution were developed in the beginning for this target group of OPOs. So it's great to be back home, seeing the OPOs using it.
Okay, great. So, is it essentially an acceleration, or more of a sustained pace even with your limited resources?
Yeah. So we will try to accelerate as fast as possible, but we will be very conscious that we want to have the right quality of people, both from our side, from our partner sites and from the OPO side to make sure that each and every OPO program is a successful program where the clinicians really get what their patients on the waiting list so deserve. So we will be very cautious on keeping a high quality.
Great. Well, thanks for taking the question. And congrats on the successful data and presentation at ISHLT. Thank you. I'll get back into the queue.
The next question comes from Jakob Lemke from SEB. Please go ahead.
My first question.
It is on the strong performance.
Is presented.
Regarding Q1, I'm wondering if you can elaborate more across the different customer groups, such as any single large customer orders, U.S. customers, as well as new customers during the quarter.
Yes, definitely can do that. It is an organic and an underlying market growth where we see an increased interest in performing more lung transplantations. And we see a changing organ pool where more and more organs become extended criteria or DCD. So that's the underlying growth we see fueling the interest. So we see both an underlying growth from existing customers. And we see that we now add new customers as well, which are slowly becoming more up and running. And we see, of course, the fast uptake in the pilot of the OPO. So those are the three reasons. We also see that with an increase in the sales footprint. In other words, with more feet on the ground closer to customers, we see an increased usage. So, it's a direct link there.
Okay.
And then also I'm wondering if there were any sort of large orders or timing effects impacting the strong Q1 sales.
I think we saw the trend in Q4, and I think that trend continued into Q1. We didn't see any huge seasonal effect or stocking/destocking during Q1 this year or Q1 last year.
So I guess my question then is, is it fair to assume then, that this is sort of a new baseline for the consumables?
That's a fair assumption. We do see an increasing interest, and we do foresee that we will continue to grow both existing and new EVLP programs. Absolutely.
Good. Then I also have a question on heart and compassionate use in Europe. I'm wondering if you can elaborate on how freely the centers can use the product right now. And also, if you can share how many centers that are live and if you have any more that you think will go live soon.
When we talk about compassionate use, there are, of course, limitations to it. And also, since this is Europe. So it's different country by country. Some are more. Hopefully soon here it's going to be more Australian-like, and some will be more restricted in terms of when you can use it or not. So it's hard to give one answer to that question because it's many countries. But we do see that more and more countries are opening up for this opportunity. And that is very, very positive. That's the key message. And then we, of course, hope that we don't need this and get the CE Mark very soon. But we see that we can keep the high interest and continue to save patients where there is no alternative to the Heart Assist. Which is the case right now.
Okay. And then I'm also wondering if there's been any new or recent dialogue with the notified body or the competent authority regarding the CE-mark. We are in dialogue with our notified body to clarify; we are not in direct contact with competent authorities in this case because they have asked for consultation and we are in contact with notified bodies.
We are in dialogue with our notified body to clarify. We are not in direct contact with competent authorities in this case because they have asked for consultation, and we are in contact with notified bodies. So the answer is yes to notified body. There has been contact. We. From what we heard from them. Yes. We should expect something here. In early summer or summer. So that's the latest we heard. So we are crossing our fingers and provide all the information we possibly can to make sure that we can get a good decision.
Okay. And then the final question is a follow-up to the earlier discussion about the potential label of the product in the US. I'm just thinking that the FDA must surely also include or consider the data you have gathered outside of the US, the randomized controlled trial, and the Australian trial. So I guess it must be a very broad label because you have the broadest data of machine perfusion products out there, right?
To start with, we're extremely proud of all the data we have. And every time we do something with extreme rigor, the clinical outcome is better than we could expect from it. So we were proud of it. It's hard to speculate on the FDA and what they will do. We will, of course, submit all data for their review. You have to. I mean, the lowest bar is for for safety reasons. And we will argue that it should be taken into consideration, at least for a future label discussion. But it's hard to speculate on the ruling from the FDA regarding the label. But if we look at the inclusion exclusion criteria in the US PRESERVE trial, it will cover the majority of donated hearts, as it is already today. So that would be that in itself would be an extremely good label.
Okay, I understand that, thank you very much. All for me today. Thanks.
Thank you.
The next question comes from Philip Wiberg from Pareto Securities. Please go ahead.
Hi. Good afternoon. First, I think I just would like to follow up on a prior question about the strength in EVLP this quarter. So I suppose the largest customer explains at least some part of the strength. Given that, I'm trying to get a better sense of the risk of ending up in a similar situation that we had last year with the stock. And you said that you don't think there are any stocking effects this quarter, but could you please just talk a little bit about that and the visibility for this largest customer.
Oh, yeah, that's a good question. We have very good visibility and very good dialogue with our largest customers, and we could see that they grow actually as much as other customers during Q1. But like us, they are also depending on the underlying market growth, but we have very good one-year visibility into what they aim to do. But they are, for the same reason as we are, dependent on the underlying market growth. And we saw that last year, in Q2, we got a dip during one quarter. So, if the momentum we see now continues, which we believe it will, we have good visibility.
Good. Thanks for that. We talked a little about the gross margins here, but perhaps one or two words on their performance, which were actually solid this quarter. But I'm just thinking about it going forward now when EVLP is growing, higher-margin thoracic products becoming a smaller part, will you be able to defend the gross margin you've had when EVLP continues to grow and takes a bigger share, and then also how you believe it's going to be affected when you launch Heart in both Europe and in the US.
That is our goal to defend the thoracic gross margins. You have a point that this quarter was extraordinary when it comes to EVLP portion out of sales. Right? So, and we have a lower margin on EVLP than on PerfusionX. But we also see the growth initiatives in the US. We have good prices on those. Speaking about the Hub model for EVLP. And also, we have not yet decided on the heart price in the US, which will be a contributor to the gross margins going forward. So, we feel that for thoracic we are in a good spot, and we will work to continue to defend the abdominal margins here in 2026, of course.
And the bigger picture is also that for our thoracic products. So heart and lung we can have more of a global price list. So we don't see any regional differences. If you compare, we're not yet there for our abdominal products. So that's something we need to work on, of course. But we are more confident, especially with heart. When starting production, there is always a slightly lower margin. But I am confident that we very soon can get the heart up and running and reach scale in production.
Alright, good. Perhaps another one to you. Note about the EBITDA margin. Stated it was 24% excluding US heart activities, but I think you said as well that there were some non-recurring costs this quarter. So could you elaborate a little bit about that? Was it only related now to Q1 and nothing going forward?
Thank you. Good question, and perhaps deserves some clarification. And this also ties into one of the questions I see in the chat as well. So now it's the same thing. So, what I referred to as non-recurring was the 7 million SEK that we spent on foundational partnership preparations, consultancy work, to prepare for the US heart launch. So, for us, that was a foundational activity. A bit of a one-off. I think the other investments we will do going forward, which we have touched upon in earlier calls as well, is really to build out the US organization to prepare for the launch. And I think that will be a more of a linear stepwise growth in opex in marketing and sales. But overall on EBITDA, last time I checked the consensus, that's where we are aiming to land for the full year of 2026.
Okay. Good. Thanks. So, just to be clear, are admin costs expected to come down from Q1 levels, with selling expenses increasing going forward?
Correct.
Okay. Good. Just last question. I was curious about the next step in direct procurement. DCD, so regarding the study presented, what are the next steps in this? I suppose there will be more studies required to get the surgeons confident in using this approach. Or what do you have to say about that?
Yeah, there will be many steps in this. The first one we hope that Prof. Filip Rega can submit a paper on how to do this. So we get a standardized approach to direct procurement. Then this was, of course, a very important step to make this data public. And also to get the interest up for direct procurement. But what we've seen is that the uptake is pretty fast. Once you got the hang of it and you've done it, and the interest to avoid all complicated other processes you would have to do, such as NRP or very expensive machinery in DCD heart transplantation, they are avoided. So you reduce costs, you reduce complexity, etc., so the interest to go this route was extremely high during the late-breaking news, and there was, unfortunately, not enough time for questions. But we will revisit that during our heart symposium today, so hopefully more people can ask questions. And then again, this is a technique that spreads surgeon to surgeon. So they will talk to each other and train each other, and they get more and more confident over time.
Okay. Good. Thank you very much. That was all for me.
Thank you. I actually have to leave.
The next question comes from Ludwig German from Handelsbanken. Please go ahead.
Hi, and thank you for taking my questions. I would like to follow up with another question on EVLP, and in line with some questions asked earlier, I would like to hear if you could say something about how you see the recovery in terms of how much has recovered now on EVLP, or if we are back at previous normal levels you mentioned. No, I don't think we have much more recovery.
No, I think we don't see much more recovery. We have to be very aggressive and find new customers and new concepts which satisfy the needs of American surgeons, such as the OPO EVLP hub model. So we will continue to build on the foundation we have now established during Q4 and Q1. I want to mention that last year there was a tough period for lung transplantation in terms of the numbers flattening out, and there was a lack of resources in the system, but again, the system reacted quickly. I think we reacted quickly to give them alternatives, alternative resources with partnerships. So I look at it more as a forward-looking exercise.
Okay. Thank you. And then I have a question. I'm not sure if you mentioned it already. I apologize if you did, but regarding the CAP trial and the 60 hearts you were allowed to enroll. You previously mentioned that you could possibly get another 60 hearts. Can you comment on the status of that now?
I can't comment further than I already did. We have applied for another 60. And we do hope that they come back as soon as possible. But we have to understand that we are under an IDE, and FDA is deciding what we can do and not do during an IDE.
Okay, I got it. That was my question. Thank you for taking my questions.
Thank you. Thanks.
Should we continue or would you like to end the call?
I continue. If the last two questions can be kept short. I know we are over time, and I actually have to leave for another meeting, but I see there are two more analysts who have questions. So I do want to give them the opportunity to ask those questions. But I will continue.
The next question comes from Oskar Bergman from Redeye. Please go ahead.
Hello, Christoffer. I will be really, really quick. We can talk later on the phone. Just wondering, R&D costs at 37 million. If that should be considered sort of a baseline going forward, or if there are any one-offs that make maybe the last couple of quarters a better baseline.
Yeah. Good question. I think it could be used as a baseline for the rest of the quarters this year, but you will see a significantly lower spend on other types of CapEx, such as material assets. We are building out and will very soon be done with investments into increasing our product capacity. So I think all in all, you will see lower CapEx in 2026. Then we foresee in 2025, which means that we are optimistic that we should be able to end the year on a cash positive level here, which would be the first time in XVIVO history.
Thanks. And then, what do you have, the CE mark? Or can you clarify the status for the heart product? Will you be able to implement any price changes in Australia and New Zealand? And if yes, roughly how much and will it be immediately after the approval? Okay.
To start with the CE mark, which will be the base for the approval in Australia, we still need to go through a review process there. Now we have a fixed reimbursement. So, with the increasing body of evidence in terms of health and hospital economics, we will, of course, improve reimbursement levels and the chance of doing that is a lot higher. After an approval. As of now, you get what you get. That is to say, with an unapproved product. That's a job that will start. It will not be immediate. So you do have to work with reimbursement in each country.
Okay. That's good enough for me. Thank you.
The next question comes from Ed Hall from Stifel. Please go ahead.
Thank you very much, everyone, for taking my questions. Just quickly on lung and how we think about it for the rest of the year. So, I think you've outlined that existing customers and new customers are showing underlying growth. And obviously looking at Q2 and Q3 are weaker comps there. Is there anything that you would point out that I may be missing outside of the trends that you've already outlined? And that would just be my first question.
Thank you. Thank you for that question. I do think that there will, of course, be seasonality, like in any business. And we also depend on the number of donors going for EVLP. But we do see, and I still state this. We do see an increased interest for lung transplantation in general and for EVLP in particular. Based on the body of evidence we see now that, for example, there was the presentation here during ISHLT that we show that you get better outcome on both DBD and DCD for EVLP if you standardize your EVLP program and EVLP protocols. If you have very clear inclusion criteria, you actually get better results from using EVLP than standard of care. So I think this growing body of evidence speaks for an ever-increasing indication for all lungs.
Perfect. No, that makes sense. And then just final question from my side. I just want to get your thoughts on how transplant surgeons are thinking about the trade-off between the increased ECMO use that we saw in the PRESERVE data for some of the DCD transplants versus what actually came out with lower severe PGD. From your talks that you've had this week at the Congress. Are there any initial thoughts you could comment on there?
No. But I think everyone was surprised that the data was as good as it was because both the donor pool and the patients were very marginal, so this was better than expected from many of the trial centers. So that was really good news. I think that we still saw a low level of severe PGD, which was really good. I think that would be the leading indicator for us, and the fact that we could also replicate that in survival data really strengthens the belief in what this product can do once it's on the market.
Perfect. Okay. So that makes sense. So it sounds like actually the lower PGD rate is really the driving force in that trade-off. It's not how I should think about it. Yeah. I mean thank you very much.
Thank you very much, everyone. Sorry for going a little bit over time. We will now end the call with the last slide where we want to thank you so much for today. And we meet next time on July 14th.



















